GlaxoSmithKline (GSK) plans to spin off its consumer healthcare division into a separate company, according to a report posted July 15 on Forbes.com.
The division targets oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements, the report said. As a separate firm, it will focus on products that serve these health categories.
The deal is expected to be completed by mid-2022, the company said.
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
